TITLE

Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease

AUTHOR(S)
Tuttle, Hillary A.; Davis-Gorman, Grace; Goldman, Steven; Copeland, Jack G.; McDonagh, Paul F.
PUB. DATE
January 2003
SOURCE
Cardiovascular Diabetology;2003, Vol. 2, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: More than seventeen million Americans are afflicted with diabetes and these people have four times the rate of coronary heart disease (CHD) as non-diabetics. Furthermore, diabetic women have a 3.8 fold greater risk for CHD compared to diabetic men. Little is known why diabetic women are at an increased risk for CHD. It is possible that diabetic women with cardiovascular disease (CVD) have a greater inflammatory response resulting in an increased platelet neutrophil conjugate formation than diabetic men with CVD or non-diabetic women with CVD. This study tested the hypothesis that platelet-neutrophil conjugates, which are associated with several cardiovascular diseases, are increased in diabetic women with CVD compared to diabetic men with CVD and non-diabetic women with CVD. Methods: Platelet-neutrophil conjugates were quantified by flow cytometry. The primary method is through direct binding of the neutrophil PSGL-1 receptor with P-selectin expressed on the platelet. Results: In this study, we found when the blood was stimulated with PAF (platelet activating factor), diabetic women without CVD demonstrated an increase in platelet-neutrophil conjugates compared to diabetic women with CVD and non-diabetic women with CVD (% conjugates: 63.3 ± 5.2 vs 46.8 ± 4.3 vs 48.6 ± 3.4, p < 0.05). The stimulation ratio was significantly increased in diabetic and non-diabetic women with CVD in comparison to diabetic men with CVD (ratio: 3.3 ± 0.4 vs 3.3 ± 0.3 vs 2.1 ± 0.3, p < 0.05). Conclusion: These results suggest that platelets and neutrophils in diabetic women have a greater potential for activation compared to diabetic men and may contribute to thrombosis/inflammation and the greater severity of coronary heart disease observed in diabetic women as compared to diabetic men.
ACCESSION #
28683659

 

Related Articles

  • Predictors of poor coronary collateral development in patients with stable coronary artery disease: Neutrophil-to-lymphocyte ratio and platelets. Gülşen, Kamil; Cerit, Levent; Özcem, Barçın; Akpınar, Onur; Akın, Fatih; Ayça, Burak; Çelik, Ömer // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Nov2015, Vol. 15 Issue 11, p960 

    A letter to the editor is presented in response to the article "Predictors of poor coronary collateral development in patients with stable coronary artery disease: Neutrophil-to-lymphocyte ratio and platelets" by Akın F. in the 2015 issue.

  • Do We Need More Research on Platelet Function in South Asian Immigrants? Dodani, Sunita // Inflammation & Allergy - Drug Targets;Dec2010, Vol. 9 Issue 5, p382 

    No abstract available.

  • Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome. Setianto, Budi Y.; Hartopo, Anggoro B.; Gharini, Putrika P. R.; Anggrahini, Dyah W.; Irawan, Bambang // Heart & Vessels;Jul2010, Vol. 25 Issue 4, p282 

    Following plaque rupture, activated platelet will induce subsequent inflammatory process including neutrophil recruitment. In vitro study demonstrated an interaction between neutrophils and platelets via a mechanism involving CD40-CD40 ligand. However, whether this mechanism exists in the...

  • PLATELETS, COAGULATION AND FIBRINOLYSIS IN DIABETIC AND NON-DIABETIC PATIENTS WITH QUIESCENT CORONARY HEART DISEASE. Badawi, H.; El-Sawy, M.; Mikhail, M.; Nomeir, A.M.; Tewfik, S. // Angiology;Sep1970, Vol. 21 Issue 8, p511 

    Examines the platelets, blood coagulation system and fibrinolytic activity in diabetic and non-diabetic patients with quiescent coronary heart disease. Role of metabolic factors in thrombosis, coagulation and fibrinolysis; Detection of increased platelet adhesiveness, increased blood clotting...

  • The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients. DiChiara, Joseph; Bliden, Kevin P.; Tantry, Udaya S.; Hamed, Miruais S.; Antonino, Mark J.; Suarez, Thomas A.; Bailon, Oscar; Singla, Anand; Gurbel, Paul A. // Diabetes;Dec2007, Vol. 56 Issue 12, p3014 

    OBJECTIVE-- Diabetic patients may have a higher prevalence of platelet aspirin resistance than nondiabetic patients. Our goal was to analyze platelet aspirin responsiveness to various aspirin doses in diabetic and nondiabetic patients. RESEARCH DESIGN AND METHODS-- We examined the effect of...

  • Comparison of the Effects of Policosanol and Atorvastatin on Lipid Profile and Platelet Aggregation in Patients with Dyslipidaemia and Type 2 Diabetes Mellitus. Castaño, Gladys; Fernández, Lilia; Mas, Rosa; Illnait, José; Mesa, Meylin; Fernández, J.C. // Clinical Drug Investigation;2003, Vol. 23 Issue 10, p639 

    Background: Diabetes mellitus and hypercholesterolaemia increase the risk for coronary heart disease, with type 2 diabetes mellitus being the most prevalent form of diabetes, frequently accompanied by dyslipidaemia. The main goal of dyslipidaemia control in nondiabetic and diabetic patients is...

  • Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes. Bhatt, Deepak L. // JAMA: Journal of the American Medical Association;9/5/2012, Vol. 308 Issue 9, p921 

    The author reflects on the ischemic events that are still common after such advancement in the field of patient with diabetes with myocardial infarction (Ml). He informs that the platelet reactivity is highlighted for this increased risk of the patients in this category. He further informs that...

  • Antiplatelet therapy and the vascular tree. Blann, A. // Heart;Jan2006, Vol. 92 Issue 1, p3 

    The article discusses the use of aspirin plus clopidogrel as an adjunct to percutaneous coronary intervention. Aspirin is effective in reducing the risk of primary and secondary cardiovascular events, such as myocardial infarction and stroke, and is a mainstay of both the adjuvant treatment of...

  • Acute coronary syndrome. Khavandi, A.; Walker, P.R. // BMJ: British Medical Journal (International Edition);3/31/2007, Vol. 334 Issue 7295, p647 

    The article presents an editorial that discusses the use of glycoprotein IIb/IIIa inhibitors in patients at high risk of acute coronary syndrome. Glycoprotein inhibitors inhibit the final pathway of platelet aggregation, so they can be used to limit the negative effects of plaque disruption. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics